Michael Thomas Henderson
Director at Spyre Therapeutics, Inc. (SYRE)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $8.0M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jun 23SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 20,00068,606 held (−23%) | $100.00 | $2.0M | -14.3% |
| May 8SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 2,404166,202 held (−1%) | $72.57 | $174K | +18.1% |
| May 8SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 33,513132,689 held (−20%) | $73.72 | $2.5M | +16.2% |
| May 8SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 24,814107,875 held (−19%) | $74.76 | $1.9M | +14.6% |
| May 8SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 19,26988,606 held (−18%) | $75.35 | $1.5M | +13.7% |
- Sell
Director Michael Thomas Henderson sold $2.0M of SYRE at $100.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Michael Thomas Henderson sold $174K of SYRE at $72.57 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Michael Thomas Henderson sold $2.5M of SYRE at $73.72 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Michael Thomas Henderson sold $1.9M of SYRE at $74.76 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Michael Thomas Henderson sold $1.5M of SYRE at $75.35 — pre-scheduled 10b5-1 plan sale.